NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...

Talk about wealth-generating powerhouses — a handful of S&P 500 companies now pull in at least $10,000 a second in revenue.

Regeneron, which is seeking FDA approval of linvoseltamab for adults with relapsed/refractory multiple myeloma that has progressed after at least three prior therapies, said the agency set a new ...

Regeneron (REGN) announced that the U.S. Food and Drug Administration has accepted for review the resubmission of the Biologics License ...

This was the stock's second consecutive day of losses.

Regeneron beats quarterly results on strong demand for eczema, eye treatments Cencora raised its annual profit forecast again on Wednesday, driven by strong demand for high-priced specialty ...

A handful of streaming services offer high-res audio. These are the best places to find better-than-CD-quality sound. My career has taken me through an eclectic assortment of fields, and connected ...

For 17-year-old Emma Wen, a senior at Great Neck North High School, the Regeneron Science Talent Search is more than a passion project. Most adults couldn't understand Wen's research, which could ...

The Regeneron Science Talent Search Celebrates ... engineering and math (STEM) competition for high school seniors. Now in its 84th year, the competition identifies extraordinary young minds ...

Last year, Regeneron named Buchholz High School senior Nathan Wei as a top 40 finalist, and he earned fourth place for his research on plastic polymers.

The Regeneron Science Talent Search Celebrates and Rewards Today's Most Talented Young Minds Driving Innovation and Progress through Scientific Exploration Now in its 84th year, the competition ...